SPD476-313

Diagnosis- Diverticulitis

C0743T26/CERTIFI Diagnosis- Crohn’s Disease

A3921043

Diagnosis- Crohn’s Disease

C87075/SECURE

Diagnosis- Crohn’s Disease

Application to Participate

Website Directory

Scheduling an Appointment

Patient Information

Pre Procedure Forms

Find Our Closest Office

 A3921043

Title: A randomized, double blind, placebo-controlled, parallel group, multi-center study to investigate the safety and efficacy of CP-690, 550 in subjects with moderate to severe Crohn’s Disease

Diagnosis: Crohn’s Disease

Primary Objective: A research study of a clinical response of a 4-week remission in the disease activity of a moderate to severe diagnosis of Crohn’s Disease and improvement of the quality of life.

Eligibility:

1. Subjects must be at least 18 years of age

2. Males and females with the clinical evidence of Crohn’s disease for at least 3 months duration and moderate to severe disease

3. A screening confirmation of diagnosis of the GI tract (ie: radiology or Endoscopy) within the past 24 months

4. Subjects receiving the following treatment are eligible providing they are on a stable treatment dose:

   • Azulfadine for at least 3 weeks prior to enrolling to study

   • Steroids (oral or rectal) for at least 2 weeks prior and on a stable dose to enrolling to the study

Treatment: Each subject will be randomized (flipping a coin) to 1 of 4 treatment arms.

** All participants will be reimbursed for travel and daily expenses, your doctor/study coordinator

will explain in detail**

If interested, please contact Jennifer Hudgins

410-494-1846 x134 or jhudgins@gastro-doc.com

Or fill out the Application to Participate